Icon (NASDAQ:ICLR) updated its FY20 earnings guidance on Tuesday. The company provided EPS guidance of $7.55-7.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.71. The company issued revenue guidance of $2.97-3.09 billion, compared to the consensus revenue estimate of $3.03 billion.Icon also updated its FY 2019
Pre-Market guidance to 6.81-6.95 EPS.
Several research firms recently weighed in on ICLR. Citigroup began coverage on Icon in a research note on Monday, January 6th. They issued a neutral rating and a $185.00 price objective for the company. UBS Group set a $160.00 price objective on Icon and gave the company a hold rating in a research note on Friday, October 25th. BidaskClub downgraded Icon from a buy rating to a hold rating in a research note on Friday. Zacks Investment Research raised Icon from a hold rating to a buy rating and set a $191.00 price objective for the company in a research note on Wednesday, December 25th. Finally, Wells Fargo & Co began coverage on Icon in a research note on Tuesday, January 7th. They issued an equal weight rating and a $180.00 price objective for the company. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $169.56.
Icon stock opened at $168.68 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.03 and a current ratio of 2.03. The stock has a fifty day moving average of $166.28 and a two-hundred day moving average of $155.24. The company has a market capitalization of $9.08 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 2.04 and a beta of 0.70. Icon has a fifty-two week low of $127.58 and a fifty-two week high of $173.00.
Icon (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $710.40 million during the quarter, compared to the consensus estimate of $709.75 million. Icon had a return on equity of 24.86% and a net margin of 13.16%. Icon’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.54 earnings per share. On average, analysts forecast that Icon will post 6.89 EPS for the current fiscal year.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: Overbought
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.